Differential effects of haloperidol on phencyclidine-induced reduction in substance P contents in rat brain regions

Synapse

Volumn 35, Issue 4, 2000, Pages 292-299

  Shirayama, Yukihiko ^a,c   Mitsushio, Hiroshi ^a,b   Takahashi, Kiyohisa ^a,b   Nishikawa, Toru ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine neurotransmission; N methyl D aspartate receptor; Prefrontal cortex; Substantia nigra

Indexed keywords

APOMORPHINE; DIZOCILPINE; HALOPERIDOL; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; SUBSTANCE P;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DOPAMINE BRAIN LEVEL; ENZYME IMMUNOASSAY; IMMUNOREACTIVITY; MALE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR BINDING; SCHIZOPHRENIA; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

ANIMALS; BRAIN; CORPUS STRIATUM; DRUG INTERACTIONS; HALOPERIDOL; LIMBIC SYSTEM; MALE; PHENCYCLIDINE; PREFRONTAL CORTEX; PROSENCEPHALON; RATS; RATS, WISTAR; SUBSTANCE P; SUBSTANTIA NIGRA; VENTRAL TEGMENTAL AREA;

EID: 0033961121     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(20000315)35:4<292::AID-SYN7>3.0.CO;2-3     Document Type: Article

References (42)

1. Arai H, Moroji T, Kosaka K, Iizuka R. 1986. Extrahypophyseal distribution of α-melanocyte stimulating hormone (α-MSH)-like immunoreactivity in postmortem brains from normal subjects and Alzheimer-type dementia patients. Brain Res 377:305-310.
2. Bannon MJ, Elliott PJ, Alpert JE, Goedert M, Iversen SD, Iversen LL. 1984. Role of endogenous substance P in stress-induced activation of mesocortical dopamine neurones. Nature 306:791-792.
3. Bowers MB Jr, Bannon MJ, Hoffman FJ Jr. 1987. Activation of forebrain dopamine systems by phencyclidine and footshock stress: evidence for distinct mechanisms. Psychopharmacology (Berl) 93: 133-135.
4. Deutch AY, Tam S-Y, Freeman AS, Bowers MB Jr, Roth RH. 1987. Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response. Eur J Pharmacol 134:257-264.
5. Hanson G, Alphs L, Pradhan S, Lovenberg. 1981. Response of striatonigral substance P systems to a dopamine receptor agonist and antagonist. Neuropharmacology 20:541-548.
6. Hong J-S, Tilson HA, Yoshikawa K. 1983. Effects of lithium and haloperidol administration on the rat brain levels of substance P. J Phamacol Exp Ther 224:590-593.
7. Javitt DC, Zukin SR. 1991. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
8. Johnson JW, Jones SM. 1990. Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential. Annu Rev Pharmacol Toxicol 30:707-750.
9. Kanazawa I, Emson PC, Cuello C. 1977. Evidence for the existence of substance P-containing fibres in striato-nigral and pallido-nigral pathways in the brain. Brain Res 119:447-453.
10. Kashihara K, Hamaraura T, Okumura K, Otsuki S. 1990. Effect of MK-801 on endogenous dopamine release in vivo. Brain Res 528: 80-82.
11. Kashiwa A, Nishikawa T, Nishijima K, Umino A, Takahashi K. 1995. Dizocilpine (MK-801) elicits a tetrodotoxin-sensitive increase in extracellular release of dopamine in rat medial frontal cortex. Neurochem Int 26:269-279.
12. Kato N, Honda Y, Ebihara S, Naruse H, Takahashi Y. 1984. Development of an enzyme immunoassay for delta sleep-inducing peptide (DSIP) and its use in the determination of the metabolic clearance rate of DSIP administered to dogs. Neuroendocrinology 39:39-44.
13. Kelly AE, Iversen SD. 1978. Behavioral response to bilateral injections of substance P into the substantia nigra of the rat. Brain Res 158:474-478.
14. Kleinman JE, Iadarola M, Govoni S, Hong J, Gillin JC, Wyatt RJ. 1983. Postmortem measurements of neuropeptides in human brain. Psychopharmacol Bull 19:375-377.
15. Le Douarin C, Oblin A, Page D, Scatton B. 1983. Influence of lithium on biochemical manifestations of striatal dopamine target cell supersensitivity induced by prolonged haloperidol treatment. Eur J Pharmacol 93:55-62.
16. Li SJ, Sivam SP, Mcginty JF, HuangYS, Hong JS. 1987. Dopaminergic regulation of tachikinin metabolism in the striatonigral pathway. J Pharmacol Expe Ther 243:792-798.
17. Li YQ, Jia HG, Rao ZR, Shi JW. 1990a. Serotonin-, substance P-or leucine-enkephalin-containing neurons in the midbrain periaqueductal gray and nucleus raphe dorsalis send projection fibers to the central amygdaloid nucleus in the rat. Neurosci Lett 120:124-127.
18. Li YQ, Rao ZR, Shi JW. 1990b. Substance P-like immunoreactive neurons in the nucleus tractus solitarii of the rat send their axons to the nucleus accumbens. Neurosci Lett 120:194-196.
19. Ljungdahl A, Hökfelt T, Nilsson G. 1978. Distribution of substance P-like immunoreactivity in the central nervous system of the rat-I. Cell bodies and nerve terminals. Neuroscience 3:861-943.
20. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-276.
21. Maurice T, Vignon J, Kamenka J-M, Chicheportiche R. 1991. Differential interaction of phencyclidine-like drugs with the dopamine uptake complex in vivo. J Neurochem 56:553-559.
22. Mele A, Fontana D, Pert A. 1997. Alterations in striatal dopamine overflow during rotational behavior induced by amphetamine, phencyclidine, and MK-801. Synapse 26:218-224.
23. Mitsushio H, Takashima M, Mataga N, Toru M. 1988. Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. J Pharmacol Exp Ther 245:982-989.
24. Mitsushio H, Shirayama Y, Nishikawa T, Takahashi K. 1993. Effects of subacute repeated injections of phencyclidine and MK-801 on substance P content in rat brain. Regul Pept 46:352-353.
25. Nishijima K, Kashiwa A, Nishikawa T. 1994. Preferential stimulation of extracellular release of dopamine in rat frontal cortex to striatum following competitive inhibition of the N-methyl-D-aspartate receptor. J Neurochem 63:375-378.
26. Nishijima K, Kashiwa A, Hashimoto A, Iwama H, Umino A, Nishikawa T. 1996. Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat frontal cortex and striatum as revealed by in vivo dialysis. Synapse 22:304-312.
27. Orosz D, Bennett JP Jr. 1990. Baseline and apomorphine-induced extracellular levels of nigral substance P are increased in an animal model of Parkinson's disease. Eur J Pharmacol 182:509-514.
28. Otsuka M, Yoshioka K. 1993. Neurotransmitter functions of mammalian tachykinins. Physiol Rev 73:229-308.
29. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates, 2nd ed. Sydney: Academic Press.
30. Ritter JK, Schmidt CJ, Gibb JW, Hanson GR. 1984. Increases of substance P-like immunoreactivity within striatal-nigral structures after subacute methamphetamine treatment. J Pharmacol Exp Ther 229:487-492.
31. Roberts GW, Ferrier IN, Lee Y, Crow TJ, Johnstone EC, Owens DGC, Hamilton AJB, McGregor G, O'Shaughnessey D, Polak JM, Bloom SR. 1983. Peptides, the limbic lobe and schizophrenia. Brain Res 288:199-211.
32. Sakanaka M, Shiosaka S, Takatsuki K, Inagaki S, Takagi H, Senba E, Kawai Y, Hara Y, Iida H, Minagawa H, Matsuzaki T, Tohyama M. 1981. Evidence for the existence of a substance P-containing pathway from the nucleus laterodorsalis tegmenti (Castaldi) to the lateral septal area of the rat. Brain Res 230:351-355.
33. Sakanaka M, Shiosaka S, Takatsuki K, Inagaki S, Hara Y, Kawai Y, Senba E, Tohyama M. 1982. Origins of substance P-containing fibers in the lateral septal area of young rats: immunohistochemical analysis of experimental manipulations. J Comp Neurol 212:268-277.
34. Sakanaka M, Shiosaka S, Takatsuki K, Tohyama M. 1983. Evidence for the existence of a substance P-containing pathway from the nucleus laterodorsalis tegmenti (Castaldi) to †the †medial frontal cortex of the rat. Brain Res 259:123-126.
35. Seeman P. 1992. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7:261-284.
36. Seiden LS, Sabol KE, Ricaurte GA. 1993. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 33:639-677.
37. Shirayama Y, Mitsushio H, Takashima M, Ichikawa H, Takahashi K. 1996. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res 739:70-78.
38. Snyder SH. 1980. Phencyclidine. Nature 285:385-386.
39. Stinus AE, Kelly AE, Iversen SD. 1978. Increased spontaneous activity following substance P infusion into A10 dopaminergic area. Nature 276:616-618.
40. Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, Ichikawa H, Kurumaji A, Takashima M, Malaga N, Ogawa A. 1988. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psych Scand 78:121-137.
41. Ujike H, Ogawa N, Otsuki S. 1988. Effects of acute and long-term treatment with methamphetamine on substance P concentration and receptor numbers in the rat brain. Brain Res 453:136-142.
42. Umino A, Takahashi K, Nishikawa T. 1998. Characterization of the phencyclidine-induced increase in prefrontal cortical dopamine metabolism in the rat. Br J Pharmacol 124:377-385.